-
Next challenge, make vaccines work against new variants: Adar Poonawalla
A lot of sacrifices were made to put the company's focus on Covishield
-
Serum Institute of India leads cross-sector Indian investments into UK
The Serum Institute of India will invest £240 million in the UK to expand its vaccine business and set up a new sales office creating a large number
-
Vaccine manufacturing a specialised process, can’t ramp up production overnight: SII
Adar Poonawalla noted that the company is making every effort to enhance production of Covishield amid the second wave of COVID in the country
-
Serum Institute of India CEO Adar Poonawalla speaks on vaccine pricing, ‘pressure’ and manufacturing plans
“The level of expectation and aggression is really unprecedented. It’s overwhelming," he said
-
Covid-19 vaccine: Centre’s flexible pricing policy will harm the public; earn producers super profits
By leaving the poor to the mercy of impecunious or uncaring state governments and profit-maximising private hospitals, the Centre has failed to live u
-
Require around Rs 3,000 crore to ramp up vaccine production: SII CEO Adar Poonawalla
We need roughly Rs 3,000 crores which is not a small figure considering we have already spent thousands of crores, says Adar Poonawalla
-
Adar Poonawalla says hopes to launch Covovax trials in India by September 2021
In August 2020, American vaccine company Novavax had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373
-
US export curbs can limit COVID-19 vaccine production, availability: Adar Poonawalla
"If we are talking about building capacity all over the world, the sharing of these critical raw materials, which just can't be replaced in a matter o
-
Serum Institute of India CEO Adar Poonawalla urges countries to be patient
Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he add
